Home » Topics » Regulatory » EMA

EMA
RSS

MAA validated for emtricitabine/rilpivirine/tenofovir combination tablet

Aug. 21, 2015

EMA to review MAA for palbociclib plus endocrine therapy for HR+/HER2- metastatic breast cancer

Aug. 21, 2015

Gamida Cell reaches agreements on phase III trial design for NiCord

Aug. 12, 2015

ProMetic Life Sciences completes first plasminogen dosing round in phase I trial

Aug. 11, 2015

Dicerna's DCR-PH1 receives orphan drug designation from the EMA

Aug. 7, 2015

EMA accepts filing of MAA for reslizumab

July 29, 2015

EMA committee hands down positive opinion for Zerbaxa

July 28, 2015

Obizur recommended for approval in Europe for acquired hemophilia A

July 28, 2015

EMA committee recommends approval of Cresemba for invasive aspergillosis and mucormycosis

July 28, 2015

EMA grants accelerated assessment to MAA for elotuzumab in MM

July 28, 2015

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 11, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 9, 2026
Skape Bio unlocks GPCR targets with de novo-designed miniproteins
BioWorld
Modulating G protein-coupled receptors (GPCRs) is one of the major challenges in biomedicine. These are flexible proteins with small, deep binding pockets. The...
Wuxi Apptec insists it’s ‘not a Chinese military company’
BioWorld
Wuxi Apptec isn’t going down without a fight after the U.S. Department of Defense added it to the Section 1260H list June 8 as a designated “Chinese military...
Researchers hit back after colleagues removed from ADA meeting
BioWorld
Former principal officers of the American Diabetes Association (ADA) have hit back at the association’s board and CEO after it prohibited the distribution of an...